Seres Therapeutics (MCRB) Sees IPO Price of $15 - $17/Share

Seres Therapeutics, Inc. (Nasdaq: MCRB) filed an amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to sell 6.25 million shares and sees an offering price of $15 - $17 per share. The company plans to list on the Nasdaq Global Market under the ticker, "MCRB."

Underwriters are Goldman, Sachs & Co., BofA Merrill Lynch, Leerink Partners, and Canaccord Genuity.

Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics.

Seres also offered the following commentary: The human microbiome is an ecology of microorganisms, including bacteria, fungi and viruses, that, when unhealthy, or dysbiotic, can leave the body more susceptible to infections, metabolic disorders, allergies, autoimmune disease, inflammation and other conditions. Our drugs are designed to restore health by repairing the function of a dysbiotic microbiome. We are initially focused on implementing our microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome, one of the most diverse microbiomes in the human body. SER-109, our lead product candidate, is designed to prevent further recurrences of Clostridium difficile infection, or CDI, a debilitating infection of the colon and, if approved by the U.S. Food and Drug Administration, or FDA, could be a first-in-field drug. In our Phase 1b/2 clinical study of SER-109 in recurrent CDI patients, 97% of patients achieved a clinical cure, which we defined as the absence of CDI requiring antibiotic treatment during the eight-week period after SER-109 dosing. SER-109 has been granted Breakthrough Therapy designation by the FDA. Breakthrough Therapy designation is intended to expedite the development and review of drugs or biologics that treat serious or life-threatening diseases or conditions and that preliminary clinical evidence indicates may be a substantial improvement over existing therapies. We initiated a Phase 2 clinical study of SER-109 for recurrent CDI and dosed the first patient in May 2015. We expect study results in the middle of 2016.

You May Also Be Interested In

• Entrata (ENT) files for proposed IPO
• Enovis to acquire eCential Robotics for up to €211M
• TXNM Energy launches $400M common stock offering